BREA, Calif. — (August 10, 2017) —
Beckman Coulter Diagnostics is pleased to announce worldwide availability of the Access 2 immunoassay system with enhanced features. Built upon a 20-year legacy of reliable and efficient performance, the Access 2 immunoassay system is a compact, random-access benchtop analyzer that delivers an extensive diagnostic-testing menu. The new features have been added to improve ease-of-use, workflow efficiencies, system reliability and customer satisfaction. Changes include the addition of an internal reagent barcode reader to minimize operating loading errors, an upgraded ergonomic workstation for operator comfort, improved fluidics tray for operational efficiency, a status light bar for notifying operators of instrument status, remote monitoring capability and a refreshed look.
"The advancements in our Access 2 immunoassay system are a great example of how our research and development team listened to our customers and enhanced an already high-performing product to best serve the needs of clinical laboratories," said John Blackwood, senior vice president, chemistry and immunoassay business unit, Beckman Coulter Diagnostics. "The Access 2 provides remote PROService connectivity, on-the-fly reagent and consumable loading, proven reliability and delivers up to 100 tests per hour. Together these features and benefits save laboratories precious time and enables physicians to deliver responsive care for patients."
Ideal for small- to medium-sized physician office laboratories, community hospitals and independent references labs or as a back-up to other primary immunoassay systems, the Access 2 is a reliable and robust system. It is designed with sample probe obstruction detection and remote monitoring capability for instrument diagnostics, maintains greater than 98 percent system availability and delivers less than 1.1 emergency service calls per year.
Beckman Coulter Diagnostics offers an extensive diagnostic testing menu for use on the Access 2 immunoassay system, with tests that cover a range of disease states to fulfill patient care needs. These tests include, adrenal disorders, anemia, bone metabolism, cardiac-related conditions, diabetes, infectious diseases, reproductive health, endocrinology, thyroid and tumor markers. The enhancements of Access 2 immunoassay system further strengthens the portfolio of clinical diagnostic solutions offered by the diagnostic companies of Danaher Corporation, which include Beckman Coulter, Cepheid, Leica Biosystems, Radiometer, and SCIEX Diagnostics. The breadth of this portfolio extends from the established to novel diagnostic technologies for clinical and anatomic pathology laboratories and point-of-care testing. With a rich history and a tradition of innovation, the diagnostic companies of Danaher remain committed to developing of new and unique diagnostic approaches for better, integrated patient care, and to helping the healthcare systems build comprehensive and efficient diagnostic services with high degree of automation, standardization and connectivity.